Plasma Chemokine C-C Motif Ligand 2 as a Potential Biomarker for Prostate Cancer

Martin Lund, Torben B. Pedersen, Søren Feddersen, Louise D. Østergaard, Charlotte A. Poulsen, Christian Enggaard, Mads H.A. Poulsen, Lars Lund*


Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

33 Downloads (Pure)


Purpose: Serum levels of the polypeptide chemokine C-C motif ligand 2 (CCL2) have previously shown potential as a prostate cancer diagnostic and prognostic biomarker. Plasma CCL2 levels may be superior to serum levels as a biomarker because of their potentially lower signal-to-noise ratio. Materials and Methods: Before initiating a large comparative study of plasma and serum CCL2 levels, we performed a prospective, diagnostic pilot study Of 133 individuals from a clinically relevant population. CCL2 plasma levels were measured using a validated assay kit. Plasma was obtained independently of digital rectal examination. Results: In this pilot study, we found no relationship between CCL2 plasma values and risk of proven prostate cancer, whereas previous studies found a strong diagnostic relationship between CCL2 serum values and prostate cancer. Conclusion: Our contribution to the existing literature strengthens the idea that early in the pathological process, CCL2 mainly circulates in large, membrane-enclosed compartments, whereas plasma CCL2 levels increase markedly during disease progression. We conclude that whereas plasma CCL2 levels are not useful as a diagnostic measure, a ratio of CCL2 plasma to serum levels may prove useful as a marker of disease progression, which warrants further study.

TidsskriftResearch and Reports in Urology
Sider (fra-til)33-38
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
We wish to thank the volunteers that donated plasma for this project. This project was partially funded by The Danish Cancer Society.


Dyk ned i forskningsemnerne om 'Plasma Chemokine C-C Motif Ligand 2 as a Potential Biomarker for Prostate Cancer'. Sammen danner de et unikt fingeraftryk.